{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:23:46Z","timestamp":1707524626941},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,11]]},"DOI":"10.7759\/cureus.26729","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T07:40:26Z","timestamp":1657525226000},"source":"Crossref","is-referenced-by-count":0,"title":["The Meaning of Lymphadenopathies During Adjuvant Durvalumab After Chemoradiotherapy for Lung Cancer: Thinking Beyond Disease Progression"],"prefix":"10.7759","author":[{"given":"Marcos","family":"Pantarotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Barata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Carvalheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Rolim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"GIl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipa","family":"Duarte-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda S","family":"Stumpf Tonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2020.02.008","article-title":"Advances in the treatment of stage III non-small cell lung cancer","volume":"41","author":"Myall NJ","year":"2020","unstructured":"Myall NJ, Das M. Advances in the treatment of stage III non-small cell lung cancer. Clin Chest Med. 2020, 41:211-22. 10.1016\/j.ccm.2020.02.008","journal-title":"Clin Chest Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4096","article-title":"Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer","volume":"26","author":"Cheema PK","year":"2019","unstructured":"Cheema PK, Rothenstein J, Melosky B, Brade A, Hirsh V. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol. 2019, 26:37-42. 10.3747\/co.25.4096","journal-title":"Curr Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov I","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, et al.. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017, 5:95. 10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14618","article-title":"Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case","volume":"34","author":"Apalla Z","year":"2021","unstructured":"Apalla Z, Kemanetzi C, Papageorgiou C, et al.. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: a narrative review apropos of a case. Dermatol Ther. 2021, 34:e14618. 10.1111\/dth.14618","journal-title":"Dermatol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.594118","article-title":"Sarcoidosis and cancer: a complex relationship","volume":"7","author":"El Jammal T","year":"2020","unstructured":"El Jammal T, Pavic M, Gerfaud-Valentin M, Jamilloux Y, S\u00e8ve P. Sarcoidosis and cancer: a complex relationship. Front Med (Lausanne). 2020, 7:594118. 10.3389\/fmed.2020.594118","journal-title":"Front Med (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000455877","article-title":"Characteristics of sarcoidosis in patients with previous malignancy: causality or coincidence?","volume":"93","author":"Arish N","year":"2017","unstructured":"Arish N, Kuint R, Sapir E, et al.. Characteristics of sarcoidosis in patients with previous malignancy: causality or coincidence?. Respiration. 2017, 93:247-52. 10.1159\/000455877","journal-title":"Respiration"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21169","article-title":"The association of lung cancer and sarcoidosis: a systematic review","volume":"14","author":"Srinivasan M","year":"2022","unstructured":"Srinivasan M, Thangaraj SR, Arzoun H, Govindasamy Kulandaisamy LB, Mohammed L. The association of lung cancer and sarcoidosis: a systematic review. Cureus. 2022, 14:e21169. 10.7759\/cureus.21169","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12991","article-title":"Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database","volume":"288","author":"Cohen Aubart F","year":"2020","unstructured":"Cohen Aubart F, Lhote R, Amoura A, Valeyre D, Haroche J, Amoura Z, Lebrun-Vignes B. Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database. J Intern Med. 2020, 288:356-62. 10.1111\/joim.12991","journal-title":"J Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-021-01477-y","article-title":"Sarcoid-like reaction in cases treated by checkpoint inhibitors","volume":"38","author":"Paydas S","year":"2021","unstructured":"Paydas S. Sarcoid-like reaction in cases treated by checkpoint inhibitors. Med Oncol. 2021, 38:29. 10.1007\/s12032-021-01477-y","journal-title":"Med Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.02.024","article-title":"Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis","volume":"131","author":"Chorti E","year":"2020","unstructured":"Chorti E, Kanaki T, Zimmer L, et al.. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis. Eur J Cancer. 2020, 131:18-26. 10.1016\/j.ejca.2020.02.024","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.07.015","article-title":"Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: a case-control study","volume":"156","author":"Cabani\u00e9 C","year":"2021","unstructured":"Cabani\u00e9 C, Ammari S, Hans S, et al.. Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: a case-control study. Eur J Cancer. 2021, 156:46-59. 10.1016\/j.ejca.2021.07.015","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02546-w","article-title":"Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital","volume":"23","author":"Torres-Jim\u00e9nez J","year":"2021","unstructured":"Torres-Jim\u00e9nez J, Esteban-Villarrubia J, Garc\u00eda-Abell\u00e1s P, et al.. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital. Clin Transl Oncol. 2021, 23:1474-80. 10.1007\/s12094-020-02546-w","journal-title":"Clin Transl Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.03.056","article-title":"Drug-induced sarcoidosis-like reactions","volume":"154","author":"Chopra A","year":"2018","unstructured":"Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions. Chest. 2018, 154:664-77. 10.1016\/j.chest.2018.03.056","journal-title":"Chest"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson N","year":"2021","unstructured":"Chanson N, Ramos-Casals M, Pundole X, et al.. Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation. Eur J Cancer. 2021, 158:208-16. 10.1016\/j.ejca.2021.05.041","journal-title":"Eur J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0372-4","article-title":"Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment","volume":"6","author":"Paolini L","year":"2018","unstructured":"Paolini L, Poli C, Blanchard S, et al.. Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment. J Immunother Cancer. 2018, 6:52. 10.1186\/s40425-018-0372-4","journal-title":"J Immunother Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.542","article-title":"Durvalumab induced sarcoid-like pulmonary lymphadenopathy","volume":"8","author":"Sanderson E","year":"2020","unstructured":"Sanderson E, Wimaleswaran H, Senko C, White S, McDonald CF. Durvalumab induced sarcoid-like pulmonary lymphadenopathy. Respirol Case Rep. 2020, 8:e00542. 10.1002\/rcr2.542","journal-title":"Respirol Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14228","article-title":"Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response","volume":"12","author":"Shi Y","year":"2021","unstructured":"Shi Y, Li J, Chen M, et al.. Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response. Thorac Cancer. 2021, 12:3433-6. 10.1111\/1759-7714.14228","journal-title":"Thorac Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S184380","article-title":"Immune checkpoint inhibitors for the treatment of unresectable stage III non-small cell lung cancer: emerging mechanisms and perspectives","volume":"10","author":"Inoue H","year":"2019","unstructured":"Inoue H, Okamoto I. Immune checkpoint inhibitors for the treatment of unresectable stage III non-small cell lung cancer: emerging mechanisms and perspectives. Lung Cancer (Auckl). 2019, 10:161-70. 10.2147\/LCTT.S184380","journal-title":"Lung Cancer (Auckl)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos I","year":"2018","unstructured":"Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol. 2018, 13:1076-82. 10.1016\/j.jtho.2018.04.031","journal-title":"J Thorac Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010017","article-title":"Liquid biopsy in non-small cell lung cancer: highlights and challenges","volume":"12","author":"Rijavec E","year":"2019","unstructured":"Rijavec E, Coco S, Genova C, Rossi G, Longo L, Grossi F. Liquid biopsy in non-small cell lung cancer: highlights and challenges. Cancers (Basel). 2019, 12:E17. 10.3390\/cancers12010017","journal-title":"Cancers (Basel)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0720-z","article-title":"The present and future of liquid biopsies in non-small cell lung cancer: combining four biosources for diagnosis, prognosis, prediction, and disease monitoring","volume":"20","author":"Bracht JW","year":"2018","unstructured":"Bracht JW, Mayo-de-Las-Casas C, Berenguer J, Karachaliou N, Rosell R. The present and future of liquid biopsies in non-small cell lung cancer: combining four biosources for diagnosis, prognosis, prediction, and disease monitoring. Curr Oncol Rep. 2018, 20:70. 10.1007\/s11912-018-0720-z","journal-title":"Curr Oncol Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff MT","year":"2018","unstructured":"Tetzlaff MT, Nelson KC, Diab A, et al.. Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018, 6:14. 10.1186\/s40425-018-0323-0","journal-title":"J Immunother Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17401","article-title":"Development of thoracic sarcoid reactions associated with complete response to anti-PD-1 therapy in a patient with advanced cutaneous squamous cell carcinoma","volume":"36 Suppl 1","author":"Gambichler T","year":"2022","unstructured":"Gambichler T, Philippou S, Scheel CH, Susok L. Development of thoracic sarcoid reactions associated with complete response to anti-PD-1 therapy in a patient with advanced cutaneous squamous cell carcinoma. J Eur Acad Dermatol Venereol. 2022, 36 Suppl 1:35-40. 10.1111\/jdv.17401","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/98971-the-meaning-of-lymphadenopathies-during-adjuvant-durvalumab-after-chemoradiotherapy-for-lung-cancer-thinking-beyond-disease-progression","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:49Z","timestamp":1707507529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/98971-the-meaning-of-lymphadenopathies-during-adjuvant-durvalumab-after-chemoradiotherapy-for-lung-cancer-thinking-beyond-disease-progression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.26729","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,11]]}}}